GenEditBio

GenEditBio Limited is a clinical-stage gene therapy biotechnology company headquartered in Hong Kong, with research laboratories and offices in Hong Kong, Beijing, and Boston. Founded in 2021, the company focuses on developing potentially curative, in vivo genome-editing therapeutic solutions for genetic diseases with unmet needs. GenEditBio's core technology platforms include novel Cas nuclease discovery and two cargo delivery systems: lipid nanoparticle (LNP) delivery and its proprietary engineered Protein Delivery Vehicle (PDV). The PDV platform enables highly precise genome editing with a high safety profile and virtually undetectable off-target effects, and has demonstrated promising results in non-human primate models for hereditary eye diseases. The company is backed by top-tier life science investors including Qiming Venture Partners, Fangyuan Capital, and HKSTP Venture Fund.